Suppr超能文献

阿替卡因颊侧浸润用于治疗有症状的下颌第一磨牙不可复性牙髓炎:它与利多卡因下牙槽神经阻滞一样有效吗?一项系统评价和Meta分析。

Articaine buccal infiltration for mandibular first molars with symptomatic irreversible pulpitis: is it as effective as inferior alveolar nerve block with lidocaine? a systematic review and meta-analysis.

作者信息

Saatchi Masoud, Mohammadi Golshan, Iranmanesh Pedram, Khademi Abbasali, Farhad Alireza, Aggarwal Vivek, Kolahi Jafar

机构信息

Department of Endodontics, Dental Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.

Department of Conservative Dentistry & Endodontics, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India.

出版信息

Clin Oral Investig. 2025 Feb 21;29(3):146. doi: 10.1007/s00784-025-06229-0.

Abstract

OBJECTIVES

This systematic review and meta-analysis aimed to compare the anesthetic efficacy of 4% articaine buccal infiltration (BI) with 2% lidocaine inferior alveolar nerve block (IANB) for mandibular first molars with symptomatic irreversible pulpitis.

METHODS

Randomized clinical trials (RCTs) comparing the anesthetic efficiency of one cartridge of 4% articaine BI (as the primary injection) with one cartridge of 2% lidocaine IANB in permanent first mandibular molars with symptomatic irreversible pulpitis were searched in five databases. The risk of bias (RoB) was evaluated using the RoB2 (Cochrane Risk of Bias Tool). A fixed-effects meta-analysis was performed using STATA software. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.

RESULTS

Out of 780 records, five RCTs were included. The meta-analysis revealed no significant difference in the success rates of articaine BI and lidocaine IANB [Risk ratio (RR) = 1.06, 95% confidence interval (CI) = (0.93, 1.20), I = 24.51%)]. The certainty of the evidence was graded as "moderate".

CONCLUSIONS

The moderate certainty of evidence suggests that the anesthetic efficacy of 4% articaine BI is comparable to 2% lidocaine IANB for mandibular first molars with symptomatic irreversible pulpitis. However, more clinical trials are needed.

CLINICAL RELEVANCE

BI with 4% articaine for mandibular first molars with symptomatic irreversible pulpitis can be an alternative for clinicians compared with 2% lidocaine IANB.

摘要

目的

本系统评价和荟萃分析旨在比较4%阿替卡因颊侧浸润麻醉(BI)与2%利多卡因下牙槽神经阻滞麻醉(IANB)用于下颌第一磨牙症状性不可逆性牙髓炎的麻醉效果。

方法

在五个数据库中检索比较1支4%阿替卡因BI(作为主要注射方式)与1支2%利多卡因IANB用于下颌第一恒磨牙症状性不可逆性牙髓炎麻醉效果的随机临床试验(RCT)。使用RoB2(Cochrane偏倚风险工具)评估偏倚风险。使用STATA软件进行固定效应荟萃分析。采用推荐分级、评估、制定与评价(GRADE)方法评估证据的确定性。

结果

在780条记录中,纳入了5项RCT。荟萃分析显示,阿替卡因BI和利多卡因IANB的成功率无显著差异[风险比(RR)=1.06,95%置信区间(CI)=(0.93,1.20),I²=24.51%]。证据确定性等级为“中等”。

结论

中等确定性的证据表明,4%阿替卡因BI用于下颌第一磨牙症状性不可逆性牙髓炎的麻醉效果与2%利多卡因IANB相当。然而,还需要更多的临床试验。

临床意义

对于下颌第一磨牙症状性不可逆性牙髓炎,与2%利多卡因IANB相比,4%阿替卡因BI可作为临床医生的一种替代选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验